Literature DB >> 8377152

New concepts for the control of tuberculosis in the twenty first century.

J L Stanford1, J M Grange.   

Abstract

As the end of the twentieth century approaches new methods are needed for the treatment and control of tuberculosis. Vaccination needs to be rethought, and BCG either improved or replaced. Chemotherapy is no longer enough to meet the needs of impoverished countries, non-compliant patients, and increasingly drug-resistant organisms. The next major step forward should logically come from immunology. Following the clear differentiation of two pathways of cellular immune response to mycobacterial challenge, and the recent description of two functional types of helper T cells, ideas of what controls them have allowed the logical development of a potential new vaccine and a new immunotherapy. These are based on a killed environmental organism, Mycobacterium vaccae NCTC 11659. With this simple preparation together with chemotherapy we may be armed as never before to face the inevitable challenge that tuberculosis will present to the twenty first century. Parallels recognised between cell death in tuberculosis and infection with the human immunodeficiency virus open the possibility that the progress made in immunotherapy in tuberculosis might be applicable to HIV. If this proves the case then we may also have control over the latest, and worst, risk factor for tuberculosis at the time we need it most.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8377152      PMCID: PMC5396745     

Source DB:  PubMed          Journal:  J R Coll Physicians Lond        ISSN: 0035-8819


  9 in total

Review 1.  BCG and tuberculosis.

Authors:  M J Bannon
Journal:  Arch Dis Child       Date:  1999-01       Impact factor: 3.791

2.  Designing a vaccine for tuberculosis.

Authors:  A S Malin; D B Young
Journal:  BMJ       Date:  1996-06-15

3.  Current trends in the management of tuberculosis.

Authors:  J M Grange; J L Stanford
Journal:  J R Soc Med       Date:  1994-12       Impact factor: 5.344

4.  Tuberculosis and HIV: light after darkness.

Authors:  J M Grange; J L Stanford; G Rook; P Onyebujoh; P A Bretscher
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

5.  Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy.

Authors:  P J Converse; A M Dannenberg; T Shigenaga; D N McMurray; S W Phalen; J L Stanford; G A Rook; T Koru-Sengul; H Abbey; J E Estep; M L Pitt
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

Review 6.  Clinically significant drug interactions with antituberculosis agents.

Authors:  J M Grange; P A Winstanley; P D Davies
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

7.  The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance.

Authors:  R Hernandez-Pando; G A Rook
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

Review 8.  The current status, challenges, and future developments of new tuberculosis vaccines.

Authors:  Wenping Gong; Yan Liang; Xueqiong Wu
Journal:  Hum Vaccin Immunother       Date:  2018-05-14       Impact factor: 3.452

Review 9.  Current and potential treatment of tuberculosis.

Authors:  S Houston; A Fanning
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.